Arrivent announces IND clearance for novel tetravalent MUC16/NAPI2B targeting ADC ARR-002 with initial focus in ovarian and endometrial cancers

Published: 2026-05-07 08:14:08 ET AVBP

Published on 05/07/2026 at 08:14 am EDT